학술논문
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
Document Type
Article
Author
Völker, Linus A.; Kaufeld, Jessica; Balduin, Gesa; Merkel, Lena; Kühne, Lucas; Eichenauer, Dennis A.; Osterholt, Thomas; Hägele, Holger; Kann, Martin; Grundmann, Franziska; Kolbrink, Benedikt; Schulte, Kevin; Gäckler, Anja; Kribben, Andreas; Boss, Kristina; Potthoff, Sebastian A.; Rump, Lars C.; Schmidt, Tilman; Mühlfeld, Anja S.; Schulmann, Karsten; Hermann, Matthias; Gaedeke, Jens; Sauerland, Kristin; Bramstedt, Jörn; Hinkel, Ulrich P.; Miesbach, Wolfgang; Bauer, Frederic; Westhoff, Timm H.; Bruck, Heike; Buxhofer-Ausch, Veronika; Müller, Tobias J.; Wendt, Ralph; Harth, Ana; Schreiber, Adrian; Seelow, Evelyn; Tölle, Markus; Gohlisch, Christopher; Bieringer, Markus; Geuther, Gesa; Jabs, Wolfram J.; Fischereder, Michael; von Bergwelt-Baildon, Anke; Schönermarck, Ulf; Knoebl, Paul; Menne, Jan; Brinkkoetter, Paul T.; Özcan, Fedai; Markau, Silke; Girndt, Matthias; Felten, Helmut; Hausberg, Martin; Brand, Marcus; Gerth, Jens; Bommer, Martin; Zschiedrich, Stefan; Schneider, Johanna; Elitok, Saban; Gawlik, Alexander; Schwenger, Vedat; Roeder, Maximilian; Radermacher, Jörg; Morgner, Anke; Herbst, Regina; von Auer, Charis
Source
Journal of Thrombosis and Haemostasis; March 2023, Vol. 21 Issue: 3 p559-572, 14p
Subject
Language
ISSN
15387933; 15387836
Abstract
The von Willebrand factor–directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety.